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In a multicenter phase 2
randomized study, we tested
the safety of high-dose pel-
vic lymph node (PLN) irra-
diation in advanced localized
prostate cancer using
intensity-modulated radia-
tion therapy (IMRT) tech-
niques. The addition of PLN
produced a similarly low
incidence of long term side-
effects as prostate only
IMRT using both clinician-
and patient-reported out-
comes. We have therefore
developed a phase 3 trial
testing the efficacy of PLN
IMRT in prostate cancer.Purpose: To establish the toxicity profile of high-dose pelvic lymph node intensity-
modulated radiation therapy (IMRT) and to assess whether it is safely deliverable at
multiple centers.
Methods and Materials: In this phase 2 noncomparative multicenter trial, 124 patients
with locally advanced, high-risk prostate cancer were randomized between prostate-
only IMRT (PO) (74 Gy/37 fractions) and prostate and pelvic lymph node IMRT
(P&P; 74 Gy/37 fractions to prostate, 60 Gy/37 fractions to pelvis). The primary
endpoint was acute lower gastrointestinal (GI) Radiation Therapy Oncology Group
(RTOG) toxicity at week 18, aiming to exclude a grade 2 or greater (G2þ) toxicity-
free rate of 80% in the P&P group. Key secondary endpoints included patient-
reported outcomes and late toxicity.
Results: One hundred twenty-four participants were randomized (62 PO, 62 P&P)
from May 2011 to March 2013. Median follow-up was 37.6 months (interquartile
range [IQR], 35.4-38.9 months). Participants had a median age of 69 years (IQR,
64-74 years) and median diagnostic prostate-specific androgen level of 21.6 ng/mL
(IQR, 11.8-35.1 ng/mL). At week 18, G2þ lower GI toxicity-free rates were 59 of
61 (96.7%; 90% confidence interval [CI], 90.0-99.4) for the PO group and 59 of 62
(95.2%; 90% CI, 88.0-98.7) for the P&P group. Patients in both groups reported simi-
larly low Inflammatory Bowel Disease Questionnaire symptoms and Vaizey inconti-
nence scores. The largest difference occurred at week 6 with 4 of 61 (7%) and 16
of 61 (26%) PO and P&P patients, respectively, experiencing G2þ toxicity. At 2 years,
the cumulative proportion of RTOG G2þ GI toxicity was 16.9% (95% CI, 8.9%-
30.9%) for the PO group and 24.0% (95% CI, 8.4%-57.9%) for the P&P group; in
addition, RTOG G2þ bladder toxicity was 5.1% (95% CI, 1.7%-14.9%) for the PO
group and 5.6% (95% CI, 1.8%-16.7%) for the P&P group.
Conclusions: PIVOTAL demonstrated that high-dose pelvic lymph node IMRT can be
delivered at multiple centers with a modest side effect profile. Although safety data
from the present study are encouraging, the impact of P&P IMRT on disease control
remains to be established.  2018 The Author(s). Published by Elsevier Inc. This is an
open access article under the CC BY license (http://creativecommons.org/licenses/by/
4.0/).Introduction
Prostate cancer is the most common cancer among men in
the United Kingdom.1 Although the majority of patients
with newly diagnosed cancer have localized disease, a
significant proportion have locally advanced disease, car-
rying a high risk of pelvic lymph node (LN) involvement.
Current treatment for such patients is long-term androgen
suppression and radiation therapy, which confers an
improvement in overall survival.2,3
Regional nodal irradiation provides a survival advantage
to patients with localized high-risk breast cancer; however,
it is uncertain whether the same effect is seen in prostate
cancer.4 Two previous randomized controlled trials5,6 failed
to demonstrate benefit from pelvic LN radiation therapy,
but these evaluations used modest radiation therapy doses
to the pelvis and had additional methodological problems.4
A recent retrospective review of the US National Cancer
Data Base7 also found no benefit of pelvic irradiation overprostate only, in terms of overall survival; however, pa-
tients with higher-risk features were more likely to have
received pelvic irradiation. Although intensity-modulated
radiation therapy (IMRT) was used in some cases, the
pelvic radiation dose was generally conservative, and me-
dian follow-up was 81 months; therefore, there might not
have been sufficient time to observe an effect on overall
survival. The radiation therapy techniques used in these
studies have since been superseded by IMRT, enabling
better shaping of dose distributions to target volume,
reducing bowel irradiation, and allowing dose escalation to
the LN.5,6
The PIVOTAL trial was designed to establish the
toxicity profile of high-dose pelvic LN IMRT and to assess
whether it was safely deliverable at multiple centers.
Patient-reported outcomes (PROs) were a key secondary
endpoint, with a focus on gastrointestinal (GI) symptoms,
to assess the effect of high-dose pelvic LN irradiation from
the patient’s perspective.
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Trial design
PIVOTAL (CRUK/10/022) is a randomized noncomparative
multicenter phase 2 trial of prostate-only (PO) versus pros-
tate and pelvic LN (P&P) IMRT for locally advanced prostate
cancer. The aims were to assess acute and late toxicity,
patient-reported toxicity, and the ability of multiple radiation
therapy centers to deliver P&P IMRT per protocol. The trial
was registered (ISRCTN48709247), approved by the West
Midlands e Edgbaston Multi-centre Research Ethics Com-
mittee (10/H1208/54), sponsored by the Institute of Cancer
Research, and conducted in accordancewith the principles of
good clinical practice. All participants provided written
informed consent. The Institute of Cancer Research Clinical
Trials and Statistics Unit (ICR-CTSU; London, UK) coor-
dinated the study and carried out central statistical data
monitoring and all analyses. The trial management group
was overseen by an independent trial steering committee.
Safety and efficacy data were reviewed regularly by an in-
dependent data monitoring committee.
Patient eligibility and selection
Eligible patients provided written informed consent
and had histologically confirmed, previously untreated,
localized adenocarcinoma of the prostate, stage T3b/T4
(or a calculated risk of pelvic LN involvement 30%)8;
received luteinizing hormoneereleasing hormone (LHRH)
analogs for 6 to 9 months before radiation therapy; had
normal blood count (Hb>11 g/dL, WBC>4  109 cells/L,
platelets > 100  109 cells/L); were 18 years old; and
had World Health Organization performance status score of
0 to 1 and prostate-specific antigen level <4 ng/mL before
randomization.
Key exclusion criteria were radiologically positive,
suspicious, or pathologically confirmed LN involvement;
castrate-resistant prostate cancer; other invasive malig-
nancy in the past 5 years (other than basal cell carcinoma);
prior pelvic radiation therapy or major pelvic surgery; life
expectancy <5 years; bilateral hip prostheses or fixation; or
the presence of a comorbid condition likely to affect
delivery of pelvic radiation therapy.
Randomization
Randomization took place by telephone to the trial coor-
dinating center within 8 weeks before start of radiation
therapy. Participants were assigned 1:1 between PO and
P&P IMRT using computer-generated random permuted
blocks of size 4, stratified by radiation therapy center.
Treatment allocation was not blinded.Treatment
Both treatment groups received 74 Gy in 37 fractions to
the prostate and involved seminal vesicles (the contempo-
raneous standard of care in the United Kingdom). Those in
the P&P group received 60 Gy in 37 fractions (1.62-Gy
fractions) to the LN regions.
Target and organ-at-risk volumes were defined according
to International Commission on Radiation Units guide-
lines.9,10 Mandatory and optimal dose constraints were
derived by literature review and defined for rectum, bowel,
bladder, and femoral heads.11-14 A vascular expansion tech-
nique was developed to identify the LN target with a “bowel
expansion” exclusion margin to reduce the inclusion of
bowel within the LN planning target volume15 so that this
was comparable to a previous phase 1/2 study.5,6 Target
volumes, dose parameters, and optimal and mandatory dose
constraints are shown in Appendix A (available online at
https://doi.org/10.1016/j.ijrobp.2018.10.003).
If individual plans failed to meet the optimal dose
constraints, target volumes and dose distributions were
reviewed locally to produce a clinically acceptable option.
If mandatory bowel dose constraints were not met, dose to
pelvic LN was dropped to 55 Gy in 37 fractions.
IMRT was conducted in accordance with the center’s
standard technique. Image-guided radiation therapy was
permitted, and the minimum treatment verification required
was appropriate onlineeoffline imaging 3 times in week 1
of treatment and subsequently at least weekly using
onlineeoffline corrections. Fiducial markers were
permitted; however, margins applied to create planning
target volumes could not be altered. Sites had to use similar
treatment protocols for both groups, and all radiation
therapy techniques were approved in advance by the trial
management group. A pretrial quality assurance program
accredited sites for treatment within PIVOTAL, and the
plans and outlines for the first 3 P&P participants per site
were reviewed by the chief investigator or delegated
accredited reviewer.
Treatment was delivered daily for 7.5 weeks. Centers
followed local bladder and bowel preparation practice
before treatment.Assessments
Clinician assessment of acute toxicity was conducted at
weeks 2, 4, 6, 8, 10, and 18 from the start of radiation
therapy. Radiation Therapy Oncology Group (RTOG)16
scoring criteria were used at each timepoint, and Com-
mon Terminology Criteria for Adverse Events (CTCAE)
version 417 were used at baseline and before radiation
therapy. The Gulliford scoring system18 was used before
radiation therapy and at week 18. All clinician-assessed
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from the start of radiation therapy. PROs were completed
on paper by participants, using the Inflammatory Bowel
Disease Questionnaire (IBDQ),19 the Vaizey Incontinence
Questionnaire,20 and the International Prostate Symptom
Score (IPSS) questionnaire21 at baseline, before radiation
therapy, and at weeks 10 and 18 and months 6, 12, 18, and
24 from the start of radiation therapy. Prostate-specific
androgen level was measured at each follow-up after
treatment, with digital rectal examination as indicated.
Patients were followed up annually after the 2-year point
for disease-related endpoints.
Statistical considerations
The primary endpoint was acute RTOG lower GI toxicity at
18 weeks from start of radiation therapy. Secondary end-
points included the ability to deliver 60 Gy in 37 fractions
to the pelvis at participating centers, late toxicity (up to
2 years), PROs, biochemical progression-free survival, time
to local progression, time to distant metastases, and overall
survival. A Simon single-stage design was used based on
data from a single-center dose escalation phase 1/2 study.5
The RTOG grade 2 (G2þ) lower GI toxicity-free rate at
18 weeks, which if true would imply that the P&P group
did not warrant further investigation, was set at 80%, with
an expected rate of 92%. With a 5% one-sided alpha and
80% power, 50 patients in the P&P group were required; if
more than 44 patients were toxicity free at 18 weeks, then
the 80% lower limit could be ruled out. A 10% noncom-
pliance rate inflated the target sample size to 55 patients in
the P&P group. An equal number of patients in the PO
group was sought to obtain prospectively collected toxicity
data for standard treatment, resulting in a total sample size
of 110 patients.
An interim analysis was conducted after 58 patients had
complete 18-week assessments. For early stopping, guid-
ance of >10% patients having a 1-week treatment break for
toxicity or >1 center being unable to achieve >50%
acceptable dose volume constraints for half of their par-
ticipants was used.
Analysis methods
The proportion of patients who were toxicity free (ie,
reporting at most RTOG lower GI G1) at 18 weeks
from the start of radiation therapy is presented by
treatment group, with 90% confidence intervals (CIs).
Kaplan-Meier methods were used to analyze time to first
reported G1þ and G2þ CTCAE and RTOG lower GI and
bladder toxicity. Patients who were event-free were
censored at the date of last clinical assessment of adverse
events or death. Two year cumulative proportions are
estimated using the Kaplan-Meier method and
incorporate events and time at risk to 27 months to
account for assessment visits occurring up to 3 monthsafter their expected visit. The Gulliford rectal scoring
system was categorized as none, mild, or moderate-to-
severe symptoms, and distributions are presented at each
assessment time by treatment group. All toxicity data
were included, regardless of the timing of the assessment
with no imputation for missing data (109 of 124 [88%]
patients had all 6 assessments). Standard scoring meth-
odologies were used for PROs.22-24 Descriptive statistics
summarized scores at each assessment. Change in PRO
scores was calculated as the total score at each time point
minus the preeradiation therapy score. A clinically sig-
nificant change was defined as 7 points for the IBDQ-
bowel domain and 4 points for both the Vaizey and
IPSS total scores.22-24 The proportion of patients
showing clinically significant improvement or deterio-
ration are presented for each assessment. Vaizey and
IPSS change scores were reversed so that, like IBDQ,
positive change scores indicate an improvement in
health-related quality of life. Because this was a non-
comparative study, no formal statistical comparisons
have been made between treatment groups. Analysis was
by assigned treatment group, with patients included if
they received at least 1 fraction of radiation therapy.
Analyses were conducted using STATA version 13.0
(StataCorp, College Station, TX).
Results
One hundred twenty-four participants were randomized (62
PO, 62 P&P) between May 2011 and March 2013 from 9
radiation therapy and 5 referring UK National Health Ser-
vice Trusts. Median follow-up was 37.6 months (inter-
quartile range, 35.4-38.9 months). Three patients were
found to be ineligible after randomization: One had an
involved perirectal LN discovered on planning computed
tomography scan; 1 had a white blood cell count of
3.3  109 cells/L before randomization; and 1 had testos-
terone >20 ng/dL before randomization. Randomized
groups were well balanced for baseline characteristics
(Table 1). In the PO group, 57 patients (92%) received
LHRH plus short-term antiandrogens, 4 patients (6%)
received maximum androgen blockade, and 1 patient
received monotherapy bicalutamide. All patients in the
P&P group received LHRH with short-term antiandrogens.
Median duration of hormone therapy before radiation
therapy was 6.8 months in both groups. Adherence to the
protocol was good (Fig. 1).
Acute toxicity
No RTOG G4 lower GI acute toxicity events were re-
ported. One patient in the P&P group had RTOG G3
proctitis, diarrhea, and rectal bleeding at 6 and 8 weeks.
Patients in the P&P group experienced more G2 toxicity
than those in the PO group; the largest difference
occurred at week 6 with 4 of 61 patients (7% and 15 of
Table 1 PIVOTAL patients baseline characteristics by treatment group (n Z 124)
Baseline characteristics
Prostate only
N Z 62
n (%)
Prostate & pelvis
N Z 62
n (%)
Total
N Z 124
n (%)
Age, y
Median (IQR) 68 (65-74) 70 (65-74) 69 (65-74)
Range 54-81 55-81 54-81
Clinical T stage*
T1c 1 (2) 1 (2) 2 (2)
T2 31 (50) 30 (48) 61 (49)
T3a 23 (37) 18 (29) 41 (33)
T3b 7 (12) 12 (19) 19 (16)
T4 0 1 (2) 1 (1)
Radiologic T stage
T1c 0 0 0
T2 15 (25) 17 (30) 32 (26)
T3a 20 (35) 22 (35) 42 (34)
T3b 25 (42) 21 (35) 46 (38)
T4 0 0 0
Not done 2 2 4y
Grade group (Gleason score)
2 (3 þ 4) 13 (21) 8 (13) 21 (17)
3 (4 þ 3) 5 (8) 6 (10) 11 (9)
4 (4 þ 4, 3 þ 5, 5 þ 3) 12 (19) 17 (27) 29 (23)
5 (4 þ 5, 5 þ 4, 5 þ 5) 32 (52) 31 (50) 63 (51)
Months from diagnosis to randomization
Median (IQR) 6.7 (6.1-7.4) 6.6 (5.8-7.6) 6.7 (5.8-7.6)
Range 4.3-10.1 4.1-17.7 4.1-17.7
PSA prediagnostic biopsy
Mean (SD) 25.2 (19.7) 26.5 (17.3) 25.9 (18.5)
Median (IQR) 21.0 (9.0-34.4) 22.0 (13.3-37.8) 21.6 (11.8-35.1)
Range 0.8-107 4.1-89.5 0.8-107
Number of high-riskz features
1 3 (5) 2 (3) 5 (4)
2 30 (48) 29 (47) 59 (48)
3 29 (47) 31 (50) 60 (48)
Abbreviations: IQR Z interquartile range; PSA Z prostate-specific antigen; SD Z standard deviation.
* Prehormone magnetic resonance imaging (MRI) scan recommended for staging. Computed tomography (CT) acceptable for lymph node assessment
but not assessment of T3b staging. One patient with clinical T3b underwent ultrasound instead of MRI.
y One patient underwent ultrasound imaging, and 1 patient underwent CT rather than MRI. Two patients had unknown reasons for no radiologic
staging.
z High-risk features: PSA level >20 ng/mL; Grade group 4 or 5 (Gleason score 8); radiologic staging T3a.
Volume -  Number -  2018 Phase 2 trial: Prostate and pelvic IMRT 561 patients (25%) with toxicity assessments in the PO
and P&O groups, respectively, experiencing G2 toxicity.
This difference declined toward week 18 (Fig. 2A) when
59 of 61 patients in the PO group (96.7%; 90% CI,
90.0%-99.4%) and 59 of 62 patients in the P&P group
(95.2%; 90% CI, 88.0%-98.7%) were free of RTOG
lower GI G2þ toxicity. The Gulliford score suggested
that patients in the P&P group experienced bowel
symptoms more commonly than did patients in the POgroup at week 18, although no statistical comparisons
were made Appendix B.
One patient in the PO group experienced RTOG G4
bladder toxicity (urinary urgency, frequency, and inability
to pass urine) at week 18; there were no G4 bladder events
reported in the P&P group. G3 bladder toxicity was re-
ported in 5 patients in the PO group and 2 patients in the
P&P group during the first 18 weeks from the start of ra-
diation therapy. The prevalence of G2þ bladder toxicity
RANDOMISED
62 allocated to Prostate only IMRT
(74Gy/37Fr)
61 evaluable for week 18
toxicity
60 evaluable for month 24
toxicity
61 evaluable for month 24
toxicity
62 evaluable for week 18
toxicity
62 allocated to Prostate & Pelvis IMRT
(74Gy/37Fr to prostate & 60Gy/37Fr to pelvis)
N = 124
60 received allocated prostate RT
2 did not receive allocated prostate RT
(one received 55Gy/20Fr due to peri-rectal lymph
nodes identified at planning CT scan, one received
64Gy/32Fr due to clinician decision to treat off-trial)
1 patient had no toxicity
assessment at week 18 due to site
error
1 patient died prior to 24 months
1 patient declined assessment
61 received allocated prostate RT
1 did not receive allocated prostate RT
(dose reduced due to proximity of bowel to PTV1)
49 received allocated 60Gy pelvis RT
11 received permitted 55Gy pelvis RT
2 did not receive allocated pelvis RT
(one no pelvis RT as unable to meet dose constraints,
one 50Gy to pelvis as unable to meet dose
constraints)
1 patient died prior to 24 months
Fig. 1. PIVOTAL Consolidated Standards of Reporting Trials flowchart.
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bladder toxicity except for week 10, when 51 of 59 patients
(86%) in the P&P group reported any toxicity compared
with only 33 of 55 patients (60%) in the PO group. Peak
acute toxicity of any grade (lower GI or bladder) occurred
at week 8 in both treatment groups.
Late toxicity
Clinician assessments of toxicity up to 24 months indicated
very low levels of GI G2þ toxicities according to both the
CTCAE and RTOG scoring systems (Fig. 3). There was 1
G4 CTCAE GI event reported at 18 months in the PO group
(constipation). Two patients had G4 RTOG bowel
toxicityd1 patient in the P&P group at 6 months (bowel
obstruction) and 1 patient in the PO group at 18 months
(bowel obstruction). One patient in the PO group had
CTCAE G3 GI toxicity (proctitis) at 24 months, but no late
G3 RTOG bowel toxicity was reported. The cumulative
proportion of RTOG G2þ GI toxicity at 2 years was 16.9%
(95% CI; 8.9%-30.9%) and 24.0 (95% CI, 8.4%-57.9%) in
the PO and P&P groups, respectively. The Gulliford scoring
system indicated that at 24 months, the majority of patients
experienced no problem with their overall bowel habits (94of 119), with 8% (10 of 119) reporting a moderate-to-
severe problem (Appendix B; available online at https://
doi.org/10.1016/j.ijrobp.2018.10.003).
RTOG bladder toxicity was infrequent to 24 months. No
G4 bladder toxicity was reported, and 1 patient in the P&P
group had a G3 event (cystitis) at 6 months. There was no
CTCAE G4 bladder toxicity. Two patients in the PO group
had CTCAE G3 bladder toxicityd1 patient (urine incon-
tinence) at 12 months and 1 patient (urine retention) at
24 months. The cumulative proportion of RTOG G2þ
bladder toxicity at 2 years was 5.1% (95% CI, 1.7%-14.9%)
and 5.6% (95% CI, 1.8%-16.7%) in the PO and P&P
groups, respectively.
Patient-reported outcomes
At week 18, patients reported similar bowel symptoms
according to the IBDQ bowel score (Table 2). IBDQ bowel
scores remained similar over time for both treatment groups
(Table 2). Week 10 had the highest proportion of patients
with a clinically significant deterioration in IBDQ bowel
score compared with the preeradiation therapy score in
both treatment groups (Fig. 4; Appendixes C and D;
available online at https://doi.org/10.1016/j.ijrobp.2018.10.
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Fig. 2. Distribution of acute Radiation Therapy Oncology Group (RTOG) toxicity and prevalence of grade 1þ, grade 2þ,
and grade 3þ toxicity at weeks 2, 4, 6, 8, 10, and 18 from the start of radiation therapy. (A) Lower gastrointestinal symptoms.
(B) Bladder symptoms.
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significant improvement in IBDQ bowel scores up to
24 months compared with patients in the PO group (no
statistical comparisons were made). The Vaizey inconti-
nence score indicated similar patient-reported experiences
at week 18, with median scores of 5 (interquartile range, 4-
8) for both treatment groups. Vaizey incontinence scores
remained similar over time for both treatment groups.
Patient-reported urinary symptoms were similar at week 18,
with 19 of 46 (41%) and 21 of 51 (41%) moderately
symptomatic and 6 of 46 (13%) and 5 of 51 (10%) severely
symptomatic in the PO and P&P groups, respectively. Week
10 had the greatest proportion of patients with a clinicallysignificant deterioration in IPSS score for both treatment
groups. The distribution of change scores appeared similar
between randomized groups and did not change greatly
over time (Appendix D; available online at https://doi.org/
10.1016/j.ijrobp.2018.10.003).Disease-related outcomes
Thirteen patients had biochemical progression: 6 in the PO
group and 7 in the P&P group. Three patients have
recommenced hormones, 2 in the PO group and 1 in the
P&P group. Six patients had local recurrence (2 PO and 4
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Fig. 3. Distribution of late (A) Common Terminology Criteria for Adverse Events (CTCAE) and (B) Radiation Therapy
Oncology Group (RTOG) lower gastrointestinal and bladder toxicity and time to first reported G1þ and G2þ toxicity.
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Fig. 3. Continued
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Table 2 Summary scores for patient reported IBDQ bowel domain total score, Vaizey total score, IPSS total score, IPSS voiding, and
storage scores at each time point by treatment group
Before radiation therapy Week 10 Week 18
PO
n (%)
P&P
n (%)
PO
n (%)
P&P
n (%)
PO
n (%)
P&P
n (%)
IBDQ bowel total score*
N 55 55 49 46 47 49
Median (IQR) 69 (67-70) 69 (67-70) 65 (61-69) 65 (61-68) 68 (65-70) 66 (62-69)
Vaizey Total scorey
N 54 54 50 49 47 52
Median (IQR) 4 (4-7) 4 (4-6) 6 (4-8) 5 (4-7) 5 (4-8) 5 (4-8)
IPSS
Mildz 29 (54) 33 (64) 9 (21) 15 (31) 21 (46) 25 (49)
Moderate 20 (37) 18 (35) 22 (50) 21 (44) 19 (41) 21 (41)
Severe 5 (9) 1 (2) 13 (30) 12 (25) 6 (13) 5 (10)
IPSS total scorex
N 54 52 44 48 46 51
Median (IQR) 7 (4-11) 6 (3-11) 11 (8-21) 12 (6-19) 9 (5-14) 8 (4-15)
Voidingk score, median (IQR) 3 (1-5) 1 (0-4) 5 (3-10) 4 (2-9) 3 (1-7) 2 (0-5)
Storage{ score, median (IQR) 4.5 (3-7) 4 (2-7) 7 (5-10) 7 (4-11) 5 (4-8) 5 (2-8)
Abbreviations: IBDQ Z Inflammatory Bowel Disease Questionnaire; IPSS Z International Prostate Symptom Score; IQR Z interquartile range;
P&P Z prostate and pelvic lymph node group; PO Z prostate-only group.
* IBDQ bowel domain total score ranges from 0 (most severe symptoms) to 70 (asymptomatic).
y Vaizey total scores range from 0 (asymptomatic) to 24 (most severe symptoms).
z IPSS score categorized as: mild Z 0 to 7; moderate Z 8 to 19; severe Z 20 to 35.
x IPSS total score ranges from 0 (asymptomatic) to 35 (most severe symptoms).
k IPSS voiding score calculated as total score of incomplete emptying, intermittency, weak stream, and straining.
{ IPSS storage score calculated as total score of frequency, urgency, and nocturia.
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7 metastatic recurrences were reported (4 PO and 3 P&P).
Two patients in the PO group died of prostate cancer. Five
patients died of other causes (1 PO, 4 P&P): respiratory
causes (2), lung cancer, glioblastoma, ischemic heart
disease, and myocardial infarction.Discussion
To our knowledge, PIVOTAL is the first randomized
controlled trial to assess toxicity prospectively in patients
receiving prostate-only and prostate and high-dose pelvic
LN IMRT. The study was derived from a single-center trial
that reported the development of P&P IMRT techniques
and safe dose escalation to pelvic LNs of doses up to
60 Gy/37 fractions.5,6 The proportion of patients who
received P&P LN IMRT and were free of acute lower GI
G2þ toxicity exceeded the predefined threshold of 80% at
week 18, and assessment of late adverse effects to 2 years
does not indicate concerns about the safety of high-dose
P&P LN IMRT.
The pelvic LN dose was approximately 7 to 10 Gy
higher than that used in previous studies.25,26 Assuming ana/b ratio of 3 Gy (1.5 Gy, 5.0 Gy), our trial gave an
equivalent dose at 2 Gy per fraction of 55.4 Gy (53.5 Gy,
56.7 Gy) to the pelvic nodal regions, compared with
48.4 Gy (47.5 Gy, 49 Gy) and 46 Gy (46 Gy, 46 Gy) in the
RTOG and Unicancer Genitourinary Group25 studies,
respectively.
Overall toxicity for the PO group was similar to that of
the 74-Gy cohort reported in the Conventional or Hypo-
fractionated High dose intensity modulated radiotherapy
for Prostate cancer trial,11,27 and toxicity in the P&P group
was comparable to results of the single-center pilot study.5,6
Acute G1/G2 bladder toxicity was similar in P&P and PO
groups, with peak reactions at 6 to 8 weeks and declining
by week 18, when there were no differences between the
randomized groups. Although acute G2 lower GI toxicity
was higher in the P&P group than in the PO group from
weeks 4 to 10, there was no difference between the
randomized groups by week 18. Rates of G2þ acute and
late toxicity were similar to, and in some cases lower than,
those observed in other trials investigating prostate
radiation therapy that did not include pelvic irradiation.28
The favorable side effect profile might relate to the pelvic
LN contouring method and bowel constraints mandated in
the trial.
Table 2 Summary scores for patient reported IBDQ bowel domain total score, Vaizey total score, IPSS total score, IPSS voiding, and
storage scores at each time point by treatment group (continued)
Month 6 Month 12 Month 18 Month24
PO
n (%)
P&P
n (%)
PO
n (%)
P&P
n (%)
PO
n (%)
P&P
n (%)
PO
n (%)
P&P
n (%)
46 51 49 45 44 43 47 48
68 (66-69) 68 (62-69) 68 (65-69) 68 (64-70) 67 (64-69) 68 (65-70) 67 (65-69) 68 (67-70)
49 51 49 49 47 43 45 49
5 (4-7) 5 (4-7) 6 (4-8) 5 (4-7) 5 (4-8) 4 (4-6) 5 (4-8) 5 (4-7)
22 (48) 28 (60) 25 (52) 28 (61) 19 (44) 28 (64) 24 (52) 26 (53)
17 (37) 14 (30) 17 (35) 16 (35) 19 (44) 14 (32) 17 (37) 19 (39)
7 (15) 5 (11) 6 (13) 2 (4) 5 (12) 2 (5) 5 (11) 4 (8)
47 48 48 48 43 44 46 49
8 (4-12) 6 (3-12) 7 (4-12) 6 (3-13) 8 (4-14) 5 (3-12) 7 (5-12) 6 (3-11)
3 (0-5) 2 (0-5) 2 (1-5.5) 2 (0-4) 3 (1-6) 2 (0-4) 3 (1-5) 1 (0-4)
6 (3-8) 4 (3-8) 5 (3-7) 4 (2-8) 5 (3-7) 3 (2-6.5) 5 (3-7) 4 (2-8)
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toxicity was similar in the 2 randomized groups. There
was no suggestion of an increasing toxicity profile over
time in either group. The CTCAE GI adverse effects
followed a similar pattern. Bladder late adverse effects
reported on the RTOG scale were low, with no difference
between the randomized groups. Although the CTCAE
assessment showed no differences between the random-
ized groups, reported scores were higher than those on the
RTOG scale. This has been noted previously by other
investigators29 and may relate to the inclusion of pre-
treatment symptoms. The RTOG assessment seems more
in keeping with the stability of the pretreatment and
posttreatment IPSS scores.
The IBDQ and Vaizey questionnaires yielded
remarkably similar results for both treatment groups at
all time points. The 10-week time point showed the worst
symptoms on all questionnaires, which is similar to the
clinician-reported data showing the worst symptoms at
8 weeks. Our results demonstrate that the majority of
patients have little change to their bowel function from
week 18 to month 24 in comparison with function before
radiation therapy. The findings of the IBDQ suggest thatthe P&P group experienced a greater severity of bowel
morbidity in a few patients, which is similar to the
clinician assessment using the RTOG toxicity score. The
advantage of using PROs in addition to clinician as-
sessments is that PROs relate to the impact of the
symptom on a particular patient’s function and quality of
life; therefore, although a toxicity might be graded
highly in a clinician-based toxicity score, it might not
particularly bother a patient, and vice versa. It is reas-
suring that the physician and PRO assessments of
toxicity are low at 2 years, with the combined assess-
ments giving greater credence to the safety of the P&P
treatment.
The safety data from the present study are encouraging;
however, any effect of high-dose pelvic LN irradiation on
disease control has yet to be established. The recently
opened PIVOTALboost trial (ISRCTN80146950, CRUK/
16/018) investigates the value of pelvic IMRT as well as the
effects of a focal intraprostatic boosts to dominant lesions
This will complement other ongoing phase 3 studies,
RTOG 09-24 (NCT01368588) and PEACE 2
(NCT01952223), and should finally determine the role of
pelvic LN radiation therapy in prostate cancer. An increase
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Fig. 4. The percentage of patients with clinically significant changes in patient-reported outcomes from preeradiation
therapy to each assessment time for the (A) Inflammatory Bowel Disease Questionnaire (IBDQ) score, (B) Vaizey score,
and (C) International Prostate Symptom Score (IPSS) score. An improvement from preeradiation therapy is indicated as a
positive percentage score and a deterioration from preeradiation therapy is indicated as a negative percentage score.
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but expected adverse effects of pelvic IMRT.References
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